NovaGo Raises $30M to Advance Spinal Cord Therapy

Zurich, Switzerland, September 2, 2026

$30M Series B Supports Clinical Development

The new financing provides NovaGo with additional resources as the company moves its lead therapeutic program through clinical development. NG004 is a human therapeutic antibody targeting Nogo-A, a protein that acts as a potent inhibitor of nerve-fiber growth in the central nervous system. By blocking Nogo-A, NovaGo aims to create conditions that can support nerve repair, regeneration and functional recovery following spinal cord injury. The company is currently evaluating NG004 in a Phase 1b clinical trial for acute spinal cord injury, and the Series B proceeds are intended to support progression toward a proof-of-concept (PoC) study in patients. The financing also represents an important development-stage milestone for NovaGo as it seeks to translate its biological approach into a potential treatment for patients with severe neurological damage. Spinal cord injury can result in permanent loss of sensation and motor function, while the limited regenerative capacity of the human CNS remains a major therapeutic challenge. NovaGo’s strategy is based on overcoming one of the biological mechanisms that restrict nerve-fiber growth after injury, potentially providing an avenue for improving neurological recovery.

NG004 Targets Nogo-A for Nerve Regeneration

NovaGo’s therapeutic approach focuses on Nogo-A, a naturally occurring inhibitor of nerve growth. The company is developing human antibodies designed to block this target and promote regeneration of damaged nerve fibers. According to NovaGo, its antibody candidates have demonstrated the ability to enhance nerve repair and functional recovery in preclinical models, supporting continued clinical investigation of the approach. NG004 has subsequently advanced into human testing, marking a transition from preclinical research toward evaluation of its safety and potential biological effects in patients. The company’s lead program is particularly focused on acute spinal cord injury, where early intervention and restoration of damaged neural pathways could have important implications for functional outcomes. The ongoing clinical development program is therefore intended to establish evidence needed to determine whether targeting Nogo-A can translate into meaningful improvements in recovery. The planned PoC study represents a further step toward determining the therapeutic potential of NG004 in the patient population.

Funding Strengthens Regenerative Medicine Pipeline

The Series B financing strengthens NovaGo’s position as it develops antibody-based regenerative medicine therapies for CNS disorders. With the additional capital, the company can continue clinical development activities surrounding NG004 while building evidence around its Nogo-A inhibition strategy. The participation of Neurimmune and Pureos, alongside existing and new investors, provides financial backing for the next phase of the company’s development program. For the broader biopharmaceutical sector, NovaGo’s financing highlights continued investor interest in therapeutic approaches aimed at neural regeneration, an area where conventional treatments often focus on managing symptoms rather than directly promoting repair of damaged neural tissue. Successful clinical validation of NG004 could establish a new therapeutic strategy for spinal cord injury and potentially support future applications of Nogo-A inhibition across neurological disorders. However, the program remains investigational, and its safety and efficacy will need to be established through clinical studies.

Source: NovaGo Therapeutics press release